Yan Leyfman: How Does a Patient's Risk of Relapse Change After Achieving Remission in DLBCL? - OncoDaily
Oncodaily,
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent…
Development and Validation of a Novel Conditional Event‐Free Survival Tool in Diffuse Large B‐Cell Lymphoma
Overview of attention for article published in American Journal of Hematology, June 2026
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (79th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (64th percentile)
Readers on
- mendeley
- 5 Mendeley